UroGen Pharma (URGN) Gains from Sales and Divestitures (2017 - 2024)
Historic Gains from Sales and Divestitures for UroGen Pharma (URGN) over the last 8 years, with Q4 2024 value amounting to $385065.0.
- UroGen Pharma's Gains from Sales and Divestitures rose 3114.13% to $385065.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $385065.0, marking a year-over-year increase of 3114.13%. This contributed to the annual value of $385065.0 for FY2024, which is 3114.13% up from last year.
- Per UroGen Pharma's latest filing, its Gains from Sales and Divestitures stood at $385065.0 for Q4 2024, which was up 3114.13% from $293626.0 recorded in Q4 2023.
- Over the past 5 years, UroGen Pharma's Gains from Sales and Divestitures peaked at $385065.0 during Q4 2024, and registered a low of $85954.0 during Q4 2020.
- In the last 5 years, UroGen Pharma's Gains from Sales and Divestitures had a median value of $293626.0 in 2023 and averaged $284417.0.
- Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first plummeted by 5327.95% in 2020, then skyrocketed by 22941.69% in 2021.
- Over the past 5 years, UroGen Pharma's Gains from Sales and Divestitures (Quarter) stood at $85954.0 in 2020, then soared by 229.42% to $283147.0 in 2021, then soared by 32.19% to $374293.0 in 2022, then fell by 21.55% to $293626.0 in 2023, then skyrocketed by 31.14% to $385065.0 in 2024.
- Its Gains from Sales and Divestitures was $385065.0 in Q4 2024, compared to $293626.0 in Q4 2023 and $374293.0 in Q4 2022.